Pharma R&D
How we serve pharma across the full R&D lifecycle — from target discovery to post-market surveillance. Built on the Apollo biobank and orchestrated through LabOS.
Highlighted = live programs. Clinical platform launches Q3 2026 — early access.
Typical engagement bands
Target Discovery $0.5–1.5M · Drug Discovery $1–3M · Preclinical $200K–1M · In Silico $100–500K · Pharmacovigilance $2.5M/yr recurring. Milestone-gated with exit options at each stage.
Target Discovery →
Novel druggable targets from Apollo multi-omics, prioritized by India-specific genetics.
Drug Discovery →
Hit ID → lead optimization via closed-loop DBTL through LabOS.
In Silico Approaches →
AlphaFold3, ESM3, generative chemistry — closed-loop with wet-lab validation.
Pre-clinical — Organoids & 3D →
Apollo-derived organoids and 3D cultures replacing animal testing (NAMs).
Clinical Platform →
Coming Q3 2026 — patient enrollment, biomarker-guided stratification.
Phase 4 / Pharmacovigilance →
Real-world evidence + India-specific PGx signal detection — $2.5M/yr recurring.